Physician profile
Brigitte Lovell
NPI 1033349170
$289,971.60
in general payments reported to CMS, 2019-2025
28 companies · $25K in 2025
The $25K reported for 2025 was more than what 99% of Orofacial Pain providers received nationally (typical 2025 total: $95.41).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39K · 2020: $39K · 2021: $81K · 2022: $44K · 2023: $31K · 2024: $31K · 2025: $25K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $64K · Travel and Lodging: $11K · Food and Beverage: $7,731 · Consulting Fee: $4,054 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $63,681.25 |
| Travel and Lodging | $11,268.41 |
| Food and Beverage | $7,730.74 |
| Consulting Fee | $4,053.75 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $128,660.03 | 2021-2025 | |
| Allergan, INC. | $68,662.42 | 2019-2022 | |
| Amgen INC. | $28,154.82 | 2019-2025 | Aimovig |
| Biohaven Pharmaceuticals, INC. | $13,156.72 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $12,912.26 | 2019-2023 | Ajovy |
| Impel Pharmaceuticals INC. | $11,832.99 | 2022-2023 | Trudhesa |
| Lilly USA, LLC | $8,250.65 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $7,728.96 | 2022 | |
| Pfizer INC. | $5,219.92 | 2023-2025 | |
| Currax Pharmaceuticals LLC | $2,006.38 | 2020 | |
| Lundbeck LLC | $1,397.11 | 2020-2025 | Vyepti |
| Supernus Pharmaceuticals, INC. | $328.46 | 2019-2022 | |
| Novo Nordisk INC | $263.57 | 2019-2025 | Wegovy |
| Upsher-Smith Laboratories LLC | $169.33 | 2019-2023 | |
| Edwards Lifesciences Corporation | $167.14 | 2024 | Sapien 3 Ultra Resilia |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $136.81 | 2025 | Tremfya |
| Amarin Pharma, INC. | $125.00 | 2019 | |
| Neurocrine Biosciences, INC. | $125.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $118.30 | 2019 | |
| Idorsia Pharmaceuticals US INC | $112.12 | 2023 | Quviviq |
| Nevro Corp. | $108.18 | 2023 | Senza |
| Genzyme Corporation | $95.52 | 2024 | |
| Vertiflex, INC. | $87.20 | 2019 | |
| Abbott Laboratories | $75.53 | 2022 | |
| Verrica Pharmaceuticals INC. | $26.41 | 2024 | Ycanth |
| Phadia US INC. | $18.71 | 2021 | |
| Medtronic, INC. | $17.69 | 2025 | Propel |
| Glaxosmithkline, LLC. | $14.37 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brigitte Lovell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.